143 related articles for article (PubMed ID: 35164277)
1. Pharmacokinetic Characterization of the DDAH1 Inhibitors ZST316 and ZST152 in Mice Using a HPLC-MS/MS Method.
Mangoni AA; Ceruti T; Frapolli R; Russo M; Fichera S; Zucchetti M; Tommasi S
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164277
[TBL] [Abstract][Full Text] [Related]
2. Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice.
Ceruti T; Frapolli R; Ghilardi C; Decio A; Dellavedova G; Tommasi S; Zucchetti M; Mangoni AA
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138547
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro.
Hulin JA; Tommasi S; Elliot D; Mangoni AA
Biomed Pharmacother; 2019 Mar; 111():602-612. PubMed ID: 30611984
[TBL] [Abstract][Full Text] [Related]
4. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance.
Tommasi S; Elliot DJ; Hulin JA; Lewis BC; McEvoy M; Mangoni AA
Sci Rep; 2017 Jun; 7(1):2871. PubMed ID: 28588208
[TBL] [Abstract][Full Text] [Related]
5. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
Hu X; Atzler D; Xu X; Zhang P; Guo H; Lu Z; Fassett J; Schwedhelm E; Böger RH; Bache RJ; Chen Y
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1540-6. PubMed ID: 21493890
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
[TBL] [Abstract][Full Text] [Related]
7. Novel Cellularly Active Inhibitor Regresses DDAH1 Induced Prostate Tumor Growth by Restraining Tumor Angiogenesis through Targeting DDAH1/ADMA/NOS Pathway.
Kami Reddy KR; Dasari C; Vandavasi S; Natani S; Supriya B; Jadav SS; Sai Ram N; Kumar JM; Ummanni R
ACS Comb Sci; 2019 Apr; 21(4):241-256. PubMed ID: 30673277
[TBL] [Abstract][Full Text] [Related]
8. DDAH1 deficiency promotes intracellular oxidative stress and cell apoptosis via a miR-21-dependent pathway in mouse embryonic fibroblasts.
Zhao C; Li T; Han B; Yue W; Shi L; Wang H; Guo Y; Lu Z
Free Radic Biol Med; 2016 Mar; 92():50-60. PubMed ID: 26806551
[TBL] [Abstract][Full Text] [Related]
9. Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt.
Zhang P; Hu X; Xu X; Chen Y; Bache RJ
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):890-7. PubMed ID: 21212404
[TBL] [Abstract][Full Text] [Related]
10. Dimethylarginine dimethylaminohydrolase-1 contributes to exercise-induced cardiac angiogenesis in mice.
Shi X; Luo X; Xu X
Biosci Trends; 2020 May; 14(2):115-122. PubMed ID: 32238672
[TBL] [Abstract][Full Text] [Related]
11. A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat.
Li R; Ren M; Lu W; Yuan Y; Li J; Zhong W
Biomed Chromatogr; 2021 Feb; 35(2):e4968. PubMed ID: 32881002
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in the dimethylarginine dimethylaminohydrolase 1 gene (DDAH1) is related to asymmetric dimethylarginine (ADMA) levels, but not to endothelium-dependent vasodilation.
Lind L; Ingelsson E; Kumar J; Syvänen AC; Axelsson T; Teerlink T
Vasc Med; 2013 Aug; 18(4):192-9. PubMed ID: 23892448
[TBL] [Abstract][Full Text] [Related]
13. Genetic and pharmacological inhibition of dimethylarginine dimethylaminohydrolase 1 is protective in endotoxic shock.
Nandi M; Kelly P; Torondel B; Wang Z; Starr A; Ma Y; Cunningham P; Stidwill R; Leiper J
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2589-97. PubMed ID: 22995517
[TBL] [Abstract][Full Text] [Related]
14. Gender-related pharmacokinetics and absolute bioavailability of diosbulbin B in rats determined by ultra-performance liquid chromatography-tandem mass spectrometry.
Yang B; Wang X; Liu W; Zhang Q; Chen K; Ma Y; Wang C; Wang Z
J Ethnopharmacol; 2013 Oct; 149(3):810-5. PubMed ID: 23954278
[TBL] [Abstract][Full Text] [Related]
15. Dissection, Optimization, and Structural Analysis of a Covalent Irreversible DDAH1 Inhibitor.
Burstein-Teitelbaum G; Er JAV; Monzingo AF; Tuley A; Fast W
Biochemistry; 2018 Jul; 57(30):4574-4582. PubMed ID: 29983043
[TBL] [Abstract][Full Text] [Related]
16. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice.
Otaegui D; Rodríguez-Gascón A; Zubia A; Cossío FP; Pedraz JL
Cancer Chemother Pharmacol; 2009 Jun; 64(1):153-9. PubMed ID: 19002463
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine.
Hu X; Xu X; Zhu G; Atzler D; Kimoto M; Chen J; Schwedhelm E; Lüneburg N; Böger RH; Zhang P; Chen Y
Circulation; 2009 Dec; 120(22):2222-9. PubMed ID: 19917889
[TBL] [Abstract][Full Text] [Related]
19. Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia.
Bakr A; Pak O; Taye A; Hamada F; Hemeida R; Janssen W; Gierhardt M; Ghofrani HA; Seeger W; Grimminger F; Schermuly RT; Witzenrath M; Brandes RP; Huang N; Cooke JP; Weissmann N; Sommer N
Am J Respir Cell Mol Biol; 2013 Sep; 49(3):491-500. PubMed ID: 23642043
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of DDAH1 improves survival, haemodynamics and organ function in experimental septic shock.
Wang Z; Lambden S; Taylor V; Sujkovic E; Nandi M; Tomlinson J; Dyson A; McDonald N; Caddick S; Singer M; Leiper J
Biochem J; 2014 Jun; 460(2):309-16. PubMed ID: 24611830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
